Parenteral nutrition
Parenteral nutrition | |
---|---|
Parenteral nutrition (PN) is the feeding of nutritional products to a person
Medical uses
Total
Absolute indications for TPN
Diseases that would require the use of TPN include:[8]
- Short bowel syndrome
- Small bowel obstruction
- Active gastrointestinal bleeding
- Pseudo-obstruction with complete intolerance to food
- High-output (defined as > 500ml/day) enteric-cutaneous fistulas (unless a feeding tube can be passed distal to the fistula)
Gastrointestinal disorders
TPN may be the only feasible option for providing nutrition to patients who do not have a functioning gastrointestinal tract or who have disorders requiring complete bowel rest, including bowel obstruction,[9] short bowel syndrome,[9] gastroschisis,[9] prolonged diarrhea regardless of its cause,[9] very severe Crohn's disease[9] or ulcerative colitis,[9] and certain pediatric GI disorders including congenital GI anomalies and necrotizing enterocolitis.[10]
In the geriatric population
There are physical, physiological, or mental differences in the geriatric population that could potentially lead to poor nutrient intake that would require them to have nutrition therapy.[11] Geriatric patients are more inclined to have delayed muscle restoration compared to the younger population. Additionally, older patients are observed to have greater cardiac and renal impairment, insulin resistance, and to have deficiencies in vitamins and crucial elements. Patients who require nutrition therapy but have contraindications for or cannot tolerate enteral nutrition are appropriate candidates for parenteral nutrition. In the geriatric population, it is indicated if oral or enteral nutrition is impossible for 3 days or when oral or enteral nutrition is likely insufficient for more than 7 to 10 days. While there are no complications of parenteral nutrition specific to the geriatric population, complications are more prevalent in this population due to increased comorbidities.[12]
In cancer
Patients who are diagnosed with cancer, whether as outpatient undergoing treatment or hospitalized, are at a greater risk of malnutrition and cachexia. Cancer-related malnutrition can be attributed to the decrease in food intake, increase in the need for energy, and the alteration of metabolism.[13] Patients should be assessed early on in their cancer treatment for any nutritional risk, such as by taking routine weights and BMI. Parenteral nutrition is indicated in cancer patients when it is not possible to access the digestive tract or if the tract is ineffective. In advanced cancer patients, the use of PN should be discussed in context of the risks and benefits, such as if the approximate survival rate is longer than 3 months and if PN would be expected to greatly improve the patients' quality of life.[13]
It is uncertain whether home parenteral nutrition improves survival or quality of life in people with malignant bowel obstruction.[14]
Duration
Short-term PN may be used if a person's digestive system has shut down (for instance by peritonitis), and they are at a low enough weight to cause concerns about nutrition during an extended hospital stay. Long-term PN is occasionally used to treat people suffering the extended consequences of an accident, surgery, or digestive disorder. PN has extended the life of children born with nonexistent or severely deformed organs.
Living with TPN
Approximately 40,000 people use TPN at home in the United States, and because TPN requires 10–16 hours to be administered, daily life can be affected.[15] Although daily lifestyle can be changed, most patients agree that these changes are better than staying at the hospital.[16] Many different types of pumps exist to limit the time the patient is "hooked up". Usually a backpack pump is used, allowing for mobility. The time required to be connected to the IV is dependent on the situation of each patient; some require once a day, or five days a week.[15]
It is important for patients to avoid as much TPN-related change as possible in their lifestyles. This allows for the best possible mental health situation; constantly being held down can lead to resentment and
Complications
TPN fully bypasses the GI tract and normal methods of nutrient absorption. Possible complications, which may be significant, are listed below. Other than those listed below, common complications of TPN include hypophosphatemia, hypokalemia, hyperglycemia, hypercapnia, decreased copper and zinc levels, elevated prothrombin time (if associated with liver injury), hyperchloremic metabolic acidosis and decreased gastrointestinal motility.[8]
Infection
TPN requires a chronic IV access for the solution to run through, and the most common complication is infection of this catheter. Infection is a common cause of death in these patients, with a mortality rate of approximately 15% per infection, and death usually results from septic shock.[17] When using central venous access, the subclavian (or axillary) vein is preferred due to its ease of access and lowest infectious complications compared to the jugular and femoral vein insertions.[6]
Catheter complications include pneumothorax, accidental arterial puncture, and catheter-related sepsis. The complication rate at the time of insertion should be less than 5%. Catheter-related infections may be minimised by appropriate choice of catheter and insertion technique.[18]
Blood clots
Chronic IV access leaves a foreign body in the vascular system, and blood clots on this IV line are common.[19] Death can result from pulmonary embolism wherein a clot that starts on the IV line breaks off and travels to the lungs, blocking blood flow.[20]
Patients on TPN who have such clots occluding their catheter may receive a
Fatty liver and liver failure
Fatty liver is usually a more long-term complication of TPN, though over a long enough course it is fairly common. The pathogenesis is due to using linoleic acid (an omega-6 fatty acid component of soybean oil) as a major source of calories.[21][22] TPN-associated liver disease strikes up to 50% of patients within 5–7 years, correlated with a mortality rate of 2–50%. The onset of this liver disease is the major complication that leads TPN patients to requiring an intestinal transplant.[23]
Hunger
Because patients are being fed intravenously, the subject does not physically eat, resulting in intense
Patients who eat food despite the inability can experience a wide range of complications, such as refeeding syndrome.[26]
Cholecystitis
Total parenteral nutrition increases the risk of acute
Gut atrophy
Infants who are sustained on TPN without food by mouth for prolonged periods are at risk for developing gut atrophy.[33]
Hypersensitivity
Hypersensitivity is a rarely described but significant complication of parenteral nutrition therapy. First reported in 1965,[34] the incidence of these reactions is speculated to be around one in 1.5 million patients who are provided parenteral nutrition.[35] There is a wide range in how and when these reactions manifest. Cutaneous manifestations are the most common presentation. Hypersensitivity is thought to occur to the individual components of TPN, with the intravenous lipid emulsion being the most frequently implicated component, followed by the multivitamin solution and the amino acid solution.[35]
Medications
Patients who are receiving intravenous parenteral nutrition may also need to receive intravenous medications as well using the same Y-site. It is important to assess the compatibility of the medications with the nutrition components. Incompatibilities can be observed physically through discoloration, phase separation, or precipitation.[36]
Metabolic complications
Metabolic complications include the
Pregnancy
Pregnancy can cause major complications when trying to properly dose the nutrient mixture. Because all of the baby's nourishment comes from the mother's blood stream, the doctor must properly calculate the dosage of nutrients to meet both recipients’ needs and have them in usable forms. Incorrect dosage can lead to many adverse, hard-to-guess effects, such as death, and varying degrees of deformation or other developmental problems.[39]
It is recommended that parenteral nutrition administration begins after a period of natural nutrition so doctors can properly calculate the nutritional needs of the fetus. Otherwise, it should only be administered by a team of highly skilled doctors who can accurately assess the fetus’ needs.[39]
Total parenteral nutrition
Solutions for total parenteral nutrition may be customized to individual patient requirements, or standardized solutions may be used. The use of standardized parenteral nutrition solutions is cost-effective and may provide better control of serum electrolytes.[40] Ideally each patient is assessed individually before commencing on parenteral nutrition, and a team consisting of specialised doctors, nurses,
For energy only,
Substance | Normal patient | High stress | Fluid-restricted |
---|---|---|---|
Amino acids | 85 g | 128 g | 75 g |
Dextrose | 250 g | 350 g | 250 g |
Lipids | 100 g | 100 g | 50 g |
Na+ | 150 mEq | 155 mEq | 80 mEq |
K+ | 80 mEq | 80 mEq | 40 mEq |
Ca2+ | 360 mg | 360 mg | 180 mg |
Mg2+ | 240 mg | 240 mg | 120 mg |
Acetate | 72 mEq | 226 mEq | 134 mEq |
Cl− | 143 mEq | 145 mEq | 70 mEq |
P | 310 mg | 465 mg | 233 mg |
MVI-12 | 10 mL | 10 mL | 10 mL |
Trace elements |
5 mL | 5 mL | 5 mL |
Components
Prepared solutions
Prepared solutions generally consist of water and electrolytes; glucose, amino acids, and lipids; essential vitamins, minerals and trace elements are added or given separately. Previously lipid emulsions were given separately but it is becoming more common for a "three-in-one" solution of glucose, proteins, and lipids to be administered.[41][42]
Added components
Individual nutrient components may be added to more precisely adjust the body contents of it. That individual nutrient may, if possible, be infused individually, or it may be injected into a bag of nutrient solution or intravenous fluids (volume expander solution) that is given to the patient.
Administration of individual components may be more hazardous than administration of pre-mixed solutions such as those used in total parenteral nutrition, because the latter are generally already balanced in regard to e.g. osmolarity and ability to infuse peripherally. Incorrect IV administration of concentrated potassium can be lethal, but this is not a danger if the potassium is mixed in TPN solution and diluted.[43]
Vitamins may be added to a bulk premixed nutrient immediately before administration, since the additional vitamins can promote spoilage of stored product.[citation needed] Vitamins can be added in two doses, one fat-soluble, the other water-soluble. There are also single-dose preparations with both fat- and water-soluble vitamins such as Cernevit.[44][45]
Minerals and trace elements for parenteral nutrition are available in prepared mixtures, such as Addaven.[46]
These additional components in parenteral nutritions, however were subject to stability checks, since they greatly affect the stability of lipid emulsions that serve as the base for these formulations. Studies have shown differences in physical and chemical stabilities of these total parenteral nutrition solutions,[47][48][49] which greatly influences pharmaceutical manufacturing of these admixtures.
Emulsifier
Only a limited number of emulsifiers are commonly regarded as safe to use for parenteral administration, of which the most important is lecithin.[medical citation needed] Lecithin can be biodegraded and metabolized, since it is an integral part of biological membranes, making it virtually non-toxic. Other emulsifiers can only be excreted via the kidneys,[citation needed] creating a toxic load. The emulsifier of choice for most fat emulsions used for parenteral nutrition is a highly purified egg lecithin,[50] due to its low toxicity and complete integration with cell membranes.
Use of egg-derived emulsifiers is not recommended for people with an egg allergy due to the risk of reaction. In situations where there is no suitable emulsifying agent for a person at risk of developing essential fatty acid deficiency, cooking oils may be spread upon large portions of available skin for supplementation by transdermal absorption.[51]
Another type of fat emulsion
History
Developed in the 1960s by Dr. Stanley Dudrick, who as a surgical resident in the University of Pennsylvania, working in the basic science laboratory of Dr. Jonathan Rhoads, was the first to successfully nourish initially Beagle puppies and subsequently newborn babies with catastrophic gastrointestinal malignancies.[53] Dr. Dudrick collaborated with Dr. Willmore and Dr. Vars to complete the work necessary to make this nutritional technique safe and successful.[54]
In 2019 the UK experienced a severe shortage of TPN bags due to safety restrictions at the sole manufacturing site, operated by Calea. The National Health Service described the situation as an emergency.[55]
See also
- Feeding tube
- Hickman line
- Intradialytic parenteral nutrition
- Intravenous therapy
- Nothing by mouth
- Intralipid
References
- ^ "BNFc is only available in the UK". NICE. Archived from the original on 2021-02-16. Retrieved 2021-02-19.
- ^ "Parenteral Manufacturing & Filling". Archived from the original on 28 November 2023. Retrieved 11 February 2024.
- ^ "Commercial Compounders". BSNA. Archived from the original on 2021-03-03. Retrieved 2021-02-19.
- ^ "Parenteral Nutrition: What it Is, Uses & Types". Cleveland Clinic. Archived from the original on 2023-10-26. Retrieved 2023-10-26.
- PMID 8289417.
- ^ a b Kozier, B., & Erb, G., & Berman, A.J., & Burke, K., & Bouchal, S. R., & Hirst, S. P.. (2004). Fundamentals of Nursing: The Nature of Nursing Practice in Canada. Canadian Edition. Prentice Hall Health: Toronto.
- ^ "American Gastroenterological Association medical position statement: parenteral nutrition". Archived from the original on 2007-07-30. Retrieved 2008-01-05.
- ^ a b c Van Gossum A, Cabre E, Hebuterne X, Jeppesen P, Krznaric Z, Messing B, Powell-Tuck J, Staun M, Nightingale J. ESPEN Guidelines on Parenteral Nutrition: Gastroenterology. Clinical Nutrition. 2009; (28):415–427.
- ^ a b c d e f The Merck Manual, 2008
- PMID 8070233.
- PMID 19464772.
- PMID 19464772.
- ^ from the original on 2021-10-17. Retrieved 2019-08-01.
- PMID 30095168.
- ^ a b c Yaworski JA. "Total Parenteral Nutrition (TPN) Frequently Asked Questions". Children's Hospital of Pittsburgh. Archived from the original on 20 November 2015. Retrieved 30 March 2014.
- ^ "Living with total parenteral nutrition (TPN) at home". Great Ormond Street Hospital. Archived from the original on 7 April 2014. Retrieved 30 March 2014.
- PMID 12882062.
- PMID 4205578.
- PMID 6413671.
- PMID 8301814.
- ^ "Evaluation of OMEGAVEN 10%® (n-3 EFA Lipid Emulsion) in Home Parenteral Nutrition-associated Liver Disease (MEGANORM)". ClinicalTrials.gov. US National Library of Medicine. 30 March 2016. Archived from the original on 27 May 2013. Retrieved 15 March 2023.
- S2CID 22406883.
- ^ Garg, M. Jones, R. M., Vaughan, R. B., Testro, A. G. (2011). Intestinal transplantation: Current status and future directions. Journal of Gastroenterology and Hepatology, 26, 1221–1228
- ISSN 2356-6744.
- Hunger (motivational state)
- ^ "Bowel Obstruction". Women's Health. 9 May 2013. Archived from the original on 9 August 2015. Retrieved 30 March 2014.
- S2CID 25507035.
- from the original on 2012-01-27. Retrieved 2011-03-25.
- PMID 8419252.
- ^ "Gastroenterology Grand Rounds". Archived from the original on 2006-09-10. Retrieved 2011-12-18.
- PMID 9352883.
- PMID 16135926. (mean follow-up time was 5.1 years)
- doi:10.1016/S1527-3369(03)00005-9. Archived from the originalon 18 March 2014. Retrieved 4 January 2016.
- PMID 14343541.
- ^ S2CID 46888724.
- S2CID 25676758.
- ^ G. Edward Morgan, Jr., Maged S. Mikhail, Michael J. MurrayClinical Anesthesiology, 4th Edition
- S2CID 1644195.
- ^ PMID 3082563.
- ^ a b Hayes EM, Cohen KR, Pinard BE, Lauletta J, Ruggiero R (2000). "Standardized versusindividually customized parenteral nutrition solutions: a comparison ofserum electrolyte values" (PDF). P&T. 25 (2): 78–80, 83, 87. Archived from the original (PDF) on 2011-07-15. Retrieved 2010-09-17.
- PMID 9739032.
- PMID 2112645.
- ^ Intravenous Potassium Guidelines (ADULTS) Archived 2011-02-24 at the Wayback Machine From RNSH Pharmacy Department. Authorised by: Margaret Duguid. Last Modified: June 2006.
- ^ "Cernevit™-12 (multivitamins for infusion)" (PDF). Food and Drug Administration. 1999. Archived (PDF) from the original on 2017-02-25. Retrieved 2015-10-19.
- ^ "Cernevit" (PDF). NPS MedicineWise. October 2014. Archived (PDF) from the original on 2016-03-04. Retrieved 2015-10-19.
- ^ "Addaven Konzentrat zur Herstellung einer Infusionslösung". Wissenschaftliche Verlagsgesellschaft Stuttgart. 2015-10-26. Archived from the original on 2015-11-17. Retrieved 2015-11-16.
- PMID 32064087.
- ISSN 1751-4991.
- PMID 24453847.
- ^ "Lecithin – An Emulsifier for Parenteral Use: TORVS Research Team". Archived from the original on 2020-11-27. Retrieved 2012-11-20.
- from the original on 2021-01-01. Retrieved 2021-02-15.
- PMID 21448206.
- PMID 4976039.
- PMID 4968812.
- ^ "Patients who cannot eat food 'fear for lives'". BBC News. 15 August 2019. Archived from the original on 16 August 2019. Retrieved 16 August 2019.